AzTrials
AzTrials

AbscessNCT01669642

Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children

A study testing Ketamine in people with Abscess and Fracture, run by Washington University School of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to find the dose of rapidly administered ketamine in 3 different pediatric age groups (2-5, 6-11 and 12-17) for abscess drainage and fracture reduction. Read more about this study

Who is it for?
Ages 2 to 17 years
Conditions the study is for
Abscess, Fracture
What is being tested?
Ketamine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
111 participants
Where
1 siteUnited States
Study dates
Apr 2012to Aug 2014
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 17 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Healthy children (ASA Physical Status I and II) 2-17 yrs old who require deep sedation for abscess incision and drainage in the St. Louis Children's Hospital Emergency Unit

Who cannot join

  • Fever (temperature ≥ 38 0Celcius) due to upper respiratory infection.
  • Obesity (BMI > 2SD for age and sex) or undernourishment (BMI < 2SD for age and sex)
  • Children with psychosis/psychiatric diagnosis (currently under the care of psychiatrist and/or taking psychiatric medication. ADHD is not an exclusion criterion)
  • Previous adverse reactions with ketamine sedation
  • Receipt of opioid analgesic in the ED (oxycodone/morphine etc) prior to sedation
  • Multiple abscesses (2 or more) requiring I \& D
Show all 9Show fewer
  • Non -English speaking families
  • Children under foster care.
  • Previous participation in current research study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • St Louis Children's hospital, Washington university

    St Louis, Missouri, 63123

Other trials in United States

About this study

Official title: Mean Effective Dose of Rapidly Administered Ketamine for Brief Pediatric Procedural Sedation

The purpose of the study is to find the dose of rapidly administered ketamine in 3 different pediatric age groups (2-5, 6-11 and 12-17) for abscess drainage and fracture reduction.

Ketamine is the most common drug administered to children to facilitate painful procedures in the emergency setting because it achieves potent sedation, pain relief and amnesia with minimal adverse cardiopulmonary effects.(1-5) However, the 1-2 hour recovery period (1,6) associated with standard ketamine administration guidelines(7) strains work flow because it requires bedside one-on-one nurse monitoring in a treatment room, tying up these limited and valuable resources. Consequently, a combination of two other drugs, propofol + fentanyl (P/F), with recovery of 20-30 minutes, is rapidly gaining popularity for procedural sedation despite more frequent respiratory depression, apnea and hypotension caused by this technique.(2,4,8,9)

Read more

The investigators believe recovery associated with our novel method for administering ketamine is significantly shorter than with the standard larger dose more slowly administered ketamine technique(7). Through the investigators clinical experience, the investigators have found rapid infusion of smaller than standard doses of ketamine safely achieves the drug's sedative effect, with the benefit of more rapid recovery due to the use of a smaller dose. However, this novel technique challenges published beliefs that time of recovery from ketamine sedation does not differ significantly with the dose administered, within the usual dose ranges, and that rapid infusion may cause respiratory depression, similar to that seen with other classes of sedative-analgesic drugs.(7,10) the investigators believe the slow infusion recommended by standard guidelines(7) requires a larger ketamine dose necessary to achieve effective sedation, and, consequently, prolongs recovery. It is the prolonged recovery that has prompted increased use of other less safe but briefer sedatives, such as propofol/fentanyl. By demonstrating patients recover rapidly with new ketamine technique, without increased adverse cardiopulmonary effects, the investigators will provide clinicians with an important new method for ketamine procedural sedation. The investigators believe clinicians will prefer more rapid recovery ketamine technique because it is safer and reduces pain and distress better than the propofol/fentanyl combination for sedation.

The investigators complete proposal requires two steps. In Step One, this proposal, the investigators will determine the minimum effective dose of rapidly infused ketamine that achieves deep sedation for at least 5 minutes in 95% of children (ED95). Two groups of patients will be studied: one group is patients undergoing abscess incision and drainage and the other group is patients undergoing fracture reduction in our Emergency Department. The investigators believe that the ED95 is different for both the groups as the severity of pain is different. The investigators will compare the safety and recovery times to published standard ketamine techniques. In the following study, Step Two, the investigators will compare this novel technique, in a blinded randomized trial using the ED95 ketamine dose determined in Step One to the standard ketamine technique to determine if the novel technique results in significantly shorter recovery without an increase in the frequency of adverse effects. The study the investigators are proposing in this submission is Step One only.

Read the detailed description

During fracture reduction in children, the investigators found less distress using ketamine+midazolam (K/M) sedation (P<0.0001) and less hypoxia (5% vs. 25%) compared to sedation with fentanyl+midazolam (F/M)(1). Others also found less hypoxia with K/M (4%) compared to propofol+fentanyl (P/F) (18-31%)(2,4). Because of the greater safety and efficacy determined in these and similar studies, ketamine is now the most common drug administered for procedural sedation of children undergoing painful procedures in the ED.(7) For the past 15 years, the investigators have sedated about 2,500 children each year with ketamine in the St. Louis Children's Emergency Department for setting broken bones, debriding burns, draining abscesses, and other very painful procedures. Midazolam was co-administered with ketamine in early studies to reduce dysphoria during recovery, but this practice has since been shown not to be beneficial. For the past 5-10 years the investigators have used ketamine without midazolam and have seen no change in how children wake up from ketamine sedation.(6,11)

Ketamine administration in the investigators previous studies (1,3) was similar to recent recommendations (1.5-2 mg/kg I.V. infused over 30-60 sec)(7). Problematically, while most of these ED procedures such as fracture reduction, burn debridement, or abscess incision and drainage, require only 5-10 minutes of deep sedation, this standard ketamine technique results in recovery periods of 60-120 minutes(1,3,6). During recovery, patients remain in treatment rooms to be monitored one-on-one by nurses for respiratory depression, airway obstruction, vomiting and other potentially life-threatening adverse events, thus tying up these limited resources(10). This long recovery has led to increased use of propofol based techniques which have more rapid recovery (20-30 minutes) but cause increased respiratory depression and hypotension and less effective sedation(2-6,9). Because of ketamine's greater safety and efficacy profile, the investigators have been interested in developing alternative ketamine administration regimens that result in more rapid recovery, similar to propofol. If successful in hastening recovery, the investigators believe that the relative lack of respiratory depression and greater analgesia with ketamine will improve patient safety by encouraging continued use of ketamine as the preferred technique for procedural sedation in children undergoing painful procedures in the ED.

To explore new techniques for hastening recovery from sedation, the investigators took advantage of the uniqueness of ketamine. Rapid administration of opioid and gabaergic drugs such as fentanyl and propofol significantly augments the drugs' beneficial effects, but it also markedly increases respiratory depression, apnea and hypotension.(13) Cautions that rapid infusion of ketamine may cause brief respiratory depression stem from early anesthesia trials using doses larger than those typically used for sedation.(7) Although not formally studied, for the past 5 years the investigators have observed no adverse effects with rapid administration of 0.5-1.5 mg/kg ketamine doses for brief painful procedures like fracture reduction and abscess incision \& drainage in children in the Emergency Unit of St. Louis Children's Hospital.

Lipophilic drugs used for procedural sedation-analgesia, such as ketamine, fentanyl, and propofol rapidly diffuse from the bloodstream into the brain. A disproportionately high percentage of the cardiac output goes to the brain, thus a large portion of a drug injected intravenously initially goes into the brain's circulation on first pass through the heart and exerts clinical effects within a single circulation time, usually < 60 seconds. The drug remaining in the bloodstream circulates throughout the body and diffuses into muscle, bone and fat, causing the blood concentration to fall. The blood-brain concentration gradient then favors drug diffusion out of the brain and the patient awakens.

Rapid infusion of sedative drugs increases central nervous system clinical effects by directing a larger portion of the drug into the brain. A rapidly injected dose of drug travels as a more concentrated bolus into the brain circulation than a slowly injected dose that is diluted by the passing blood. With rapid injection, therefore, the initial blood-brain concentration gradient is greater and a larger portion of the dose initially enters the brain, causing deeper sedation. Smaller doses, rapidly injected, therefore can be used to achieve deep sedation similar to that of larger doses injected more slowly. With the smaller dose, the blood-brain concentration gradient subsequently reverses more rapidly and "wake up time" is shorter. Because rapid increases in brain concentration of ketamine does not cause respiratory depression, unlike that seen with fentanyl or propofol, this rapid infusion technique can be used with ketamine.

The purpose of this research project is to determine formally the minimum dose of ketamine that, when rapidly infused, achieves 5 minutes of deep sedation in 95% of patients (ED95). The investigators will use the up and down method (15) which is a standard method in anesthesiology to find the mean effective dose. Five minutes is typically enough time to perform these brief painful procedures. The investigators anticipate the ED95 will be smaller than the standard recommended ketamine dose and thus patients will wake up faster.

Of special note, determination of the "standard dose and rate of administration of ketamine"(7) has been based upon our and others' studies in which the dose and rate of infusion of ketamine were not carefully controlled and, in fact, varied widely(1,3,4,7). Thus, the "standard recommendation for administration of ketamine" is somewhat anecdotal and has not been precisely determined. Our proposed study will be the first to precisely determine a minimum effective ketamine dose.

Conditions
Abscess, Fracture
Being tested
Ketamine
Keywords
ketamine sedation, pediatric, abscess drainage, fracture reduction
Medical subject headings
Abscess, Fractures, Bone

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KetamineDrug

    Also called Ketalar

    participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.

Study groups in NCT01669642
Study groupRoleWhat they receive
KetamineExperimentalparticipants who get the ketamine sedation will be enrolled. there is no control or comparison group.
Receives: Drug: Ketamine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Median Effective Dose (ED50) and ED95 of Rapidly Administered Ketamine

    ED50 is the dose of rapidly administered ketamine that achieves effective sedation in 50% of patients. ED95 is the dose of ketamine that can provide effective sedation in 95% of children undergoing abscess drainage or fracture reduction. ED95 will be calculated for the 3 age groups (2-5, 6-11 and 12-17) independently for both the procedures: abscess drainage and fracture reduction.

    Measured: Dose administration through 5 minutes

  2. ED95

    ED95 is the dose of ketamine effective for 95% of children. this outcome is estimated from ED50.

    Measured: Dose administration through 5 minutes

Secondary outcomes (2)
  1. Vomiting

    patients who experienced vomiting while in the ED or after discharge

    Measured: Administration of ketamine through 2 week follow up call

  2. Number of Participants With Wisconsin Sedation Scale Score of 2 or Less at 1 Minute After First Dose of Ketamine

    This is a measure of sedation effectiveness; to assess the effectiveness of first dose of ketamine administered.

    Possible values for the scale range from 0 to 6. A sedation score of 2 or less is considered adequate sedation. Values more than 2 indicate state of inadequate sedation. higher values indicate the need for additional doses of sedation.

    Patients who achieved a score of 2 or less are considered effective sedation and a score of >2 are considered ineffective sedations.

    Measured: Dose administration through 1 minute

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Aug 2012 (estimated)
  2. Study startApr 2012
  3. Primary completionAug 2014
  4. Study completionAug 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
111 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01669642
Sponsor's protocol ID
201112017
Status last verified
Apr 2019
First submitted
8 Aug 2012
Last updated
25 Apr 2019
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Ketamine in people with Abscess and Fracture, run by Washington University School of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Mar 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Median Effective Dose (ED50) and ED95 of Rapidly Administered Ketamine (time frame: Dose administration through 5 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in